Drugs / Canakinumab
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (5) | US (FDA) | ILARIS | — | 2013-05-09 – 2023-08-25 | fda.gov ↗ |
| Approved | EU (EMA) | Ilaris | — | 2009-10-23 | europa.eu ↗ |
| Approved | US (FDA) | ILARIS | — | 2009-06-17 | fda.gov ↗ |
Trials 100 · started per year
today
US approved 2009
EU approved 2009
1
4
7
4
9
11
12
6
3
3
2
6
2
3
5
4
8
4
2
1
1
1
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04028245 | Aug 2019 → Mar 2025 | clear cell renal carcinoma | Columbia University | Completed | No outcome recorded |
| Phase 110 trials | ||||||
| Phase 1 | NCT05984602 | Jul 2023 → Sep 2025 overdue | malignant pancreatic neoplasm | NYU Langone Health | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04810611 | Jun 2021 → Apr 2024 | myelodysplastic syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT04581343 | Nov 2020 → Nov 2022 | pancreatic ductal adenocarcinoma | Pancreatic Cancer Action Network | Completed | No outcome recorded |
| Phase 1 | NCT03742349 | Jan 2019 → Feb 2023 | triple-negative breast carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT03064854 | May 2017 → Jul 2021 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT02900664 | Aug 2016 → Mar 2021 | colorectal cancer, non-small cell lung carcinoma, triple-negative breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02775994 | Aug 2016 → Jan 2020 | PFAPA syndrome | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT01589029 | Apr 2012 → Nov 2014 | proliferative diabetic retinopathy | PD Dr. med. Stephan Michels | Terminated | No outcome recorded |
| Phase 1 | NCT00421226 | Dec 2006 → Oct 2007 | — | Novartis | Completed | No outcome recorded |
| Phase 1 | NCT00503022 | Jul 2006 → ? | wet macular degeneration | Novartis | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT04798339 | Mar 2021 → May 2025 overdue | myelodysplastic syndrome | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03936894 | May 2019 → Apr 2024 | Duchenne muscular dystrophy | Children's National Research Institute | Unknown | No outcome recorded |
| Phase 1/2 | NCT00505089 | Aug 2007 → May 2009 | rheumatoid arthritis | Novartis | Terminated | No outcome recorded |
| Phase 1/2 | NCT00581945 | Jan 2007 → May 2010 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 1/2 | NCT00426218 | Dec 2006 → Mar 2010 | juvenile idiopathic arthritis | Novartis | Completed | No outcome recorded |
| Phase 249 trials | ||||||
| Phase 2 | NCT06691217 | Mar 2026 → Jan 2029 expected | atherosclerotic cardiovascular disease, vasculitis | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07138898 | Dec 2025 → Jan 2028 expected | rheumatic disorder | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 2 | NCT06038526 | Mar 2024 → Feb 2026 | lung carcinoma | Peter Shields | Completed | No outcome recorded |
| Phase 2 | NCT05641831 | Feb 2023 → Dec 2028 expected | clonal hematopoiesis of indeterminate potential | Uma Borate | Recruiting | No outcome recorded |
| Phase 2 | NCT05467800 | Aug 2022 → Oct 2026 expected | myelofibrosis, primary myelofibrosis | John Mascarenhas | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05237713 | Apr 2022 → Feb 2024 | anemia, myelodysplastic syndrome | University of Leipzig | Terminated | No outcome recorded |
| Phase 2 | NCT04795466 | Oct 2021 → Mar 2024 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT04814368 | Aug 2021 → Jun 2024 | osteoarthritis, knee | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT04789681 | Jul 2021 → Dec 2027 expected | lung carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04905316 | May 2021 → Jul 2026 | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT04239157 | Aug 2020 → Dec 2026 expected | chronic myelomonocytic leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT03968419 | Nov 2019 → Apr 2022 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT03484923 | Sep 2018 → Dec 2022 | melanoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02961218 | Apr 2017 → Jun 2019 | sickle cell disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02888080 | Dec 2016 → Mar 2019 | pulmonary sarcoidosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02980263 | Nov 2016 → Nov 2017 | Kawasaki disease | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT02756650 | Jun 2016 → Jan 2019 | Behcet disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02272946 | Sep 2015 → Feb 2021 | HIV infectious disease, cardiovascular disorder | Priscilla Hsue, MD | Completed | No outcome recorded |
| Phase 2 | NCT02007252 | Dec 2013 → Oct 2015 | abdominal aortic aneurysm | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01805960 | Jun 2013 → Dec 2016 | atrial fibrillation | University Hospital, Basel, Switzerland | Terminated | No outcome recorded |
| Phase 2 | NCT01731990 | Oct 2012 → Aug 2016 | peripheral arterial disease | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02204293 | Jun 2012 → May 2018 | adult-onset Still disease | Charite University, Berlin, Germany | Terminated | No outcome recorded |
| Phase 2 | NCT01635127 | Jun 2012 → Dec 2016 | chronic idiopathic urticaria | University of Zurich | Unknown | No outcome recorded |
| Phase 2 | NCT01390350 | Jul 2011 → Dec 2017 | Schnitzler syndrome | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 2 | NCT01245127 | May → Aug 2011 | Schnitzler syndrome | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 2 | NCT01303380 | Mar 2011 → Jul 2014 | mevalonate kinase deficiency | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01322321 | Mar → Jun 2011 | type 1 diabetes mellitus | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT01364389 | Feb 2011 → Jan 2013 | inflammatory disease, polymyalgia rheumatica | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01302795 | Feb 2011 → Aug 2014 | pyoderma gangrenosum | University of Zurich | Completed | No outcome recorded |
| Phase 2 | NCT01276522 | Jan → May 2011 | Schnitzler syndrome | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01148797 | Dec 2010 → Feb 2012 | familial Mediterranean fever | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01250171 | Nov 2010 → Sep 2011 | dry eye syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00947427 | Oct 2010 → Apr 2013 | type 1 diabetes mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT01242813 | Oct 2010 → Jun 2014 | TNF receptor 1-associated periodic fever syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01170936 | Jul 2010 → Sep 2011 | urticaria, vasculitis | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 2 | NCT01160822 | Apr 2010 → Jul 2011 | osteoarthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01088880 | Apr 2010 → Aug 2011 | familial Mediterranean fever | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01068860 | Feb → Aug 2010 | glucose intolerance, type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00995930 | Dec 2009 → Feb 2014 | atherosclerosis, prediabetes syndrome, type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00927810 | Jun 2009 → Aug 2010 | gout | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00819585 | Dec 2008 → Aug 2010 | gout | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00798369 | Nov 2008 → Aug 2009 | gout | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00663169 | Apr 2008 → Oct 2009 | gout | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00605475 | Dec 2007 → Sep 2010 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00554606 | Oct 2007 → Aug 2009 | rheumatoid arthritis | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00504595 | May 2007 → Sep 2008 | rheumatoid arthritis | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00487825 | Mar 2007 → Dec 2008 | rheumatoid arthritis | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00424346 | Nov 2006 → Sep 2008 | rheumatoid arthritis | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00487708 | Jan 2005 → Jul 2008 | autoinflammatory syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05535738 | Nov 2022 → Jan 2027 expected | allergic contact dermatitis | Wei-Che Ko | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00900146 | Apr 2009 → Nov 2010 | type 2 diabetes mellitus | Novartis | Terminated | No outcome recorded |
| Phase 331 trials | ||||||
| Phase 3 | NCT05725343 | Feb → Apr 2022 | lung cancer | Mario Negri Institute for Pharmacological Research | Terminated | No outcome recorded |
| Phase 3 | NCT04717635 | Mar 2021 → Apr 2025 | adult-onset Still disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04362813 | Apr → Sep 2020 | cytokine release syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04229004 | Jan 2020 → Feb 2025 | pancreatic adenocarcinoma | Pancreatic Cancer Action Network | Completed | No outcome recorded |
| Phase 3 | NCT03626545 | Jan 2019 → Jan 2021 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT03631199 | Dec 2018 → Aug 2021 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT03447769 | Mar 2018 → Mar 2022 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT02911857 | Oct 2016 → Jan 2017 | periodic fever syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02396212 | May 2015 → Mar 2017 | systemic-onset juvenile idiopathic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02296424 | Nov 2014 → Oct 2016 | systemic-onset juvenile idiopathic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02334748 | Nov 2014 → Aug 2018 | hereditary periodic fever syndrome, systemic-onset juvenile idiopathic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02059291 | Jun 2014 → Jul 2017 | hereditary periodic fever syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01676948 | Jan 2013 → Jan 2015 | systemic-onset juvenile idiopathic arthritis | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT01593527 | Sep 2012 | gout | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT01576367 | Jan 2012 → Oct 2015 | CINCA syndrome, Muckle-Wells syndrome, familial cold autoinflammatory syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01470989 | Nov 2011 → May 2013 | gout | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01431638 | Aug 2011 → May 2013 | gout | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01362608 | Jun 2011 → May 2015 | gout | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01356602 | May 2011 → Sep 2012 | gout | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01327846 | Apr 2011 → Mar 2017 | atherosclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01302860 | Nov 2010 → Nov 2014 | CINCA syndrome, Muckle-Wells syndrome, familial cold autoinflammatory syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01105507 | Aug 2010 → May 2012 | cryopyrin-associated periodic syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01080131 | Mar → Nov 2010 | gout | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01029652 | Dec 2009 → Oct 2010 | gout | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00991146 | Oct 2009 → Feb 2012 | CINCA syndrome, Muckle-Wells syndrome, familial cold autoinflammatory syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00891046 | Sep 2009 → Dec 2014 | systemic-onset juvenile idiopathic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00886769 | Jul 2009 → Dec 2010 | systemic-onset juvenile idiopathic arthritis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00889863 | Jul 2009 → Sep 2011 | systemic-onset juvenile idiopathic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00770601 | Jan 2009 → Feb 2011 | CINCA syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00685373 | May 2008 → Apr 2010 | Muckle-Wells syndrome, familial cold autoinflammatory syndrome | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00465985 | Apr 2007 → Oct 2008 | Muckle-Wells syndrome | Novartis | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05080218 | Nov 2021 → Apr 2024 | psoriatic arthritis, spondyloarthropathy | Jeffrey Curtis | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04476706 | — | cytokine release syndrome | Novartis Pharmaceuticals | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06481189 Comparator | Sep 2022 → Mar 2023 | — | AO GENERIUM | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00619905 Comparator | Dec 2003 → Aug 2005 | rheumatoid arthritis | Novartis | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04365153 Comparator | Apr 2020 → Feb 2021 | COVID-19 | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03775109 Comparator | Feb 2019 → Mar 2023 | alcoholic hepatitis | Imperial College London | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06497491 Comparator | Dec 2023 → May 2025 | adult-onset Still disease | AO GENERIUM | Completed | No outcome recorded |
| Phase 3 | NCT05401578 Comparator | Apr 2023 → May 2026 overdue | hypoglycemia | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
| Phase 3 | NCT04510493 Comparator | Oct 2020 → Aug 2021 | COVID-19, type 2 diabetes mellitus | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
Press releases naming this drug 11 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-08-15 | Novartis Pharmaceuticals | Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer novartis.com ↗ |
| 2021-10-25 | Novartis Pharmaceuticals | Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer novartis.com ↗ |
| 2021-03-09 | Novartis Pharmaceuticals | Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer novartis.com ↗ |
| 2019-06-03 | Novartis Pharmaceuticals | Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials novartis.com ↗ |
| 2017-11-13 | Novartis Pharmaceuticals | Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants novartis.com ↗ |
| 2017-08-27 | Novartis Pharmaceuticals | Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk novartis.com ↗ |
| 2017-08-27 | Novartis Pharmaceuticals | Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned novartis.com ↗ |
| 2017-06-22 | Novartis Pharmaceuticals | Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack novartis.com ↗ |
| 2016-12-16 | Novartis Pharmaceuticals | Novartis receives positive CHMP recommendation for Ilaris® to treat rare diseases in adults and children called Periodic Fever Syndromes novartis.com ↗ |
| 2016-09-23 | Novartis Pharmaceuticals | Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions novartis.com ↗ |
| 2016-04-27 | Novartis Pharmaceuticals | Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes novartis.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 113 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | canakinumab | “Canakinumab, a fully human interleukin-1β monoclonal antibody, approved for the cryoporin-associated periodic syndrome, may offer a practical advantage because its half-life of...” PMID 22901459 ↗ Aug 201287“An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)” NCT01676948 ↗ “Pharmacokinetics and pharmacodynamics of the anti-interleukin (IL)-1β monoclonal antibody, canakinumab, in gouty arthritis patients from three studies are reported.” PMID 24122883 ↗ Sep 2013 “Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger.” PMID 31161734 ↗ Sep 2019 “Canakinumab is a human anti-interleukin-1beta monoclonal antibody.” PMID 19494217 ↗ Jun 2009 “Canakinumab 150 mg s.c.” NCT01593527 ↗ |
| Known as | ACZ885 | “A Randomized, Controlled Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are...” NCT01080131 ↗33“Canakinumab (ACZ885) will be dosed at 200mg via subcutaneous injection every 3 weeks x 3 injections that will start with concurrent chemoradiation, followed by 200mg via...” NCT04905316 ↗ “This 8-week study is designed to determine the target dose of canakinumab (ACZ885) for the management of acute flare in gout patients who are contraindicated to Non-Steroidal...” NCT00798369 ↗ “An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)” NCT01676948 ↗ “Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).” PMID 21356079 ↗ Feb 2011 “This study combines canakinumab (ACZ885), a high-affinity human anti-interleukin-1β (IL-1β) monoclonal antibody (mAb)” NCT04581343 ↗ “A 12 Weeks Randomized, Controlled Core Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares” NCT01029652 ↗ “Patients will receive a standard dose at an equivalent of 2 mg/kg s.c. of canakinumab (ACZ885) every 8 weeks.” NCT01576367 ↗ “An Open-label Extension Study of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis” NCT00891046 ↗ “Participants received an initial dose of 1 mg/kg canakinumab (ACZ885) via intravenous infusion.” NCT00581945 ↗ “Patients will be treated on demand with canakinumab (ACZ885) in this extension study.” NCT00927810 ↗ “Canakinumab (ACZ885)” NCT01731990 ↗ “Canakinumab (ACZ885)” NCT01302860 ↗ “Canakinumab (ACZ885)” NCT02911857 ↗ “Canakinumab (ACZ885)” NCT00685373 ↗ “Canakinumab, ACZ885” NCT01362608 ↗ |
| Known as | ACZ885D | “canakinumab (company code: ACZ885D)” NCT01105507 ↗ |
| Known as | AIN457 | “Canakinumab (AIN457)” NCT02911857 ↗ |
| Known as | Ilaris | “This is a multi-center double-blind placebo-controlled study to assess the efficacy and safety of canakinumab (trade name Ilaris®), a high-affinity monoclonal antibody that...” NCT01390350 ↗8“The pilot study evaluates the efficacy and safety of Canakinumab (ILARIS®) in subjects with proliferative diabetic retinopathy secondary to type 1 and 2 diabetes.” NCT01589029 ↗ “Canakinumab (Ilaris®, Novartis Switzerland) will be used in the recommended standard dose of 150 mg subcutaneously once.” NCT05401578 ↗ “Canakinumab (Ilaris, Novartis Pharma) is a fully human anti-interleukin-1-bèta monoclonal antibody.” NCT01245127 ↗ “Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy” NCT03936894 ↗ “single doses of canakinumab (trade name Ilaris®), a high-affinity monoclonal antibody” NCT01170936 ↗ “CANAKINUMAB (ILARIS®)” NCT06691217 ↗ |
| Action | Inhibit | “Canakinumab is a fully human anti-interleukin IL-1beta monoclonal antibody, being investigated for the treatment of rheumatoid arthritis (RA).” PMID 21736751 ↗ Jul 2011 |
| Modality | Monoclonal antibody | “Canakinumab is a fully human anti-interleukin IL-1beta monoclonal antibody, being investigated for the treatment of rheumatoid arthritis (RA).” PMID 21736751 ↗ Jul 2011 |
| Route | Intravenous | “administered via intravenous infusion” NCT00421226 ↗ |
| Target | IL1B | “Canakinumab, a fully human anti-IL-1β antibody, produces sustained selective inhibition of IL-1β.” PMID 21356079 ↗ Feb 2011 |